CEL-SCI Stock Forum

$CEL-SCI(CVM.US)$
NEWS
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI has received FDA approval for a confirmatory study of its cancer immunotherapy Multikine for head and neck cancer patients, based on strong Phase 3 data showing a 73% survival rate with Multikine. The study will enroll 212 patients and aims to confirm the results of the Phase 3 trial, paving the way for potential approval. The FDA acknowledged the unmet ne...

$CEL-SCI(CVM.US)$ Reuters· just
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

$CEL-SCI(CVM.US)$ has released an update.
CEL-SCI Corporation has successfully completed an offering of 3,875,000 common stock shares at $2.00 each, raising $7.75 million before expenses. This capital will primarily fund the development of their Multikine product, as well as for general corporate purposes and working capital. The offering, which closed on February 13, 2024, was facilitated by ThinkEquity LLC, acting as the representative for the underwriters. The shares were sold...

$CEL-SCI(CVM.US)$Moomoo 24/7· 5 mins ago
European Medicines Agency Grants CEL-SCI A Waiver Of Strict Pediatric Requirements, Clearing The Path Towards Marketing Authorization For Multikine

$CEL-SCI(CVM.US)$ UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer